N-(furan-2-ylmethyl)-2,2-dimethyl-propionamide | 152937-53-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: N-(furan-2-ylmethyl)-2,2-dimethyl-propionamide
• 英文别名: N-(furan-2-ylmethyl)-2,2-dimethylpropanamide
• CAS: 152937-53-6
• 化学式: C₁₀H₁₅NO₂
• mdl: MFCD00995718
• 分子量: 181.235
• InChiKey: UJDVDJGLVYJPQL-UHFFFAOYSA-N

物化性质

• 熔点：
  34.2-35.2 °C(Solv: heptane (142-82-5); ethyl acetate (141-78-6))
• 沸点：
  329.1±25.0 °C(Predicted)
• 密度：
  1.023±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(furan-2-ylmethyl)-2,2-dimethyl-propionamide 在 正丁基锂 、 二异丙胺 作用下， 以 四氢呋喃 、 hexanes 为溶剂， 以47%的产率得到N-((1E,3E)-5-oxopenta-1,3-dienyl)pivalamide
  参考文献：
  名称：

  Synthesis of N-Acyl-5-aminopenta-2,4-dienals via Base-Induced Ring-Opening of N-Acylated Furfurylamines: Scope and Limitations

  摘要：

  N-Acylation of furfurylamines provided 1, which on double deprotonation with LDA led to the formation of N-acyl-5-aminopenta-2,4-dienals 2 via an isomerization involving opening of the furan ring. The scope and limitations of the procedure were examined by considering the influence of substituents on the carbonyl group and also on the heterocycle moiety. The efficacy of the reaction was shown to be very dependent on the nature of these groups.

  DOI：

  10.1021/jo100634z
• 作为产物：
  描述：

  2-呋喃甲胺 、 特戊醛 在 bis(1,5-cyclooctadiene)rhodium(I) tetrafluoroborate 、 caesium carbonate 、 甲基丙烯酸甲酯 、 三环己基膦 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 以77%的产率得到N-(furan-2-ylmethyl)-2,2-dimethyl-propionamide
  参考文献：
  名称：

  铑受阻的醛和醇的氧化酰胺化反应

  摘要：

  已经开发出铑与空间受阻的醛和醇催化的氧化酰胺化反应，以合成在α位含有季碳的酰胺。使用脂肪族和芳香族的多种胺亲核试剂，并以良好或优异的收率得到相应的酰胺。最后，进行机理研究以了解两个催化循环。

  DOI：

  10.1021/acscatal.6b02541

文献信息

• HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS
  申请人：CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD.

  公开号：US20170253614A1

  公开（公告）日：2017-09-07

  A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.

  一系列丙型肝炎病毒（HCV）抑制剂及其组合物，以及在制备用于治疗慢性HCV感染的药物时的应用。特别是一系列用作NS5A抑制剂的化合物，以及在药物制剂中的组合物和用途。
• DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS
  申请人：Molteni Valentina

  公开号：US20090012094A1

  公开（公告）日：2009-01-08

  Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

  本文介绍了一种包含二芳胺结构特征的化合物。还介绍了制备这种化合物的方法，使用这种化合物调节c-kit受体活性的方法，以及包含这种化合物的制药组合物和药物。本文还介绍了使用这种化合物、制药组合物和药物治疗和/或预防和/或抑制和/或改善与c-kit受体活性相关的病理学和/或症状学疾病或状况的方法。
• Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
  申请人：Muller W. George

  公开号：US20080064876A1

  公开（公告）日：2008-03-13

  The present invention provides processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-diones which are useful, for example, for preventing or treating diseases or conditions related to an abnormally high level or activity of TNF-α. The invention can provide cost-effective and efficient processes for the commercial production of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-diones, including, but not limited to, 4-[(N,N-dimethylhydrazono)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione, 4-aminomethyl-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione, and 4-[(acylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-diones.

  本发明提供了制备取代的2-(2,6-二氧代哌啶-3-基)异吲哚-1,3-二酮的方法，该方法可用于预防或治疗与TNF-α水平或活性异常高相关的疾病或病况。该发明可以提供成本效益高且高效的方法，用于商业生产取代的2-(2,6-二氧代哌啶-3-基)异吲哚-1,3-二酮，包括但不限于4-[(N,N-二甲基肼)甲基]-2-(2,6-二氧代哌啶-3-基)异吲哚-1,3-二酮、4-氨甲基-2-(2,6-二氧代哌啶-3-基)异吲哚-1,3-二酮和4-[(酰胺基)甲基]-2-(2,6-二氧代哌啶-3-基)异吲哚-1,3-二酮。
• HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR
  申请人：Miyaji Katsuaki

  公开号：US20090253751A1

  公开（公告）日：2009-10-08

  Compounds effective for preventing, treatment or improving diseases against which activation of the thrombopoietin receptor is effective are provided. A compound represented by the formula (I) (wherein R 1 , R 2 , R 3 , L 1 , L 2 , X and Y are defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

  提供了一种用于预防、治疗或改善激活血小板生成素受体有效对抗的疾病的化合物。该化合物由式(I)所表示（其中R1、R2、R3、L1、L2、X和Y在描述中被定义），该化合物的互变异构体、前药或药物可接受的盐或其溶剂化物。
• Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors
  申请人：Molteni Valentina

  公开号：US20070149538A1

  公开（公告）日：2007-06-28

  Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

  本文描述了包含二芳胺结构特征的化合物。还描述了制备这种化合物的方法，使用这种化合物调节c-kit受体活性的方法，以及包含这种化合物的药物组合物和药物。本文还描述了使用这种化合物、药物组合物和药物治疗和/或预防和/或抑制和/或改善与c-kit受体活性相关的病理学和/或症状学疾病或状况的方法。